Adoptive cell therapy (ACT) has come a long way, but it still struggles to treat solid tumors effectively—mainly due to problems like tumor antigen heterogeneity and low target expression. Our team, with over 10 years of experience in CAR and TCR therapies, is developing a smart, logic-gated targeting system to overcome these challenges. This new approach is designed to detect and respond to tumors that have mixed or low antigen levels, aiming to boost both precision and treatment success. We're also working on an in vivo viral delivery platform that can reprogram the patient’s own T cells to recognize and attack cancer cells. This method could also be combined with other therapies to further improve results.